Issues for Statisticians in Conducting Analyses and Translating Results for Quality of Life End Points in Clinical Trials
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Quality of life (QOL) end points in pharmaceutical clinical trials are at a crossroads. On the one hand, much has been learned in recent years of how to efficiently and effectively measure patient QOL. On the other hand, investigators and regulatory agencies still struggle with exactly how to assess the results of QOL end points and other patient-reported outcomes. Statisticians are often left in the position of having to bridge the gap between investigators who want to assess patient QOL and regulatory bodies who want a sound scientific rationale and analysis plan for doing so. Unfortunately, little has been written specifically for the statistical audience to assist in this translation. The purpose of this paper is to attempt to bridge this gap. We will describe the language and methods that have been successful in translating the psychometric and statistical challenges into understandable findings for investigators and regulatory agencies. One of the most important advances is the development of a general guideline for assessing clinical significance, namely the "half standard deviation" method based on the empirical rule effect size (ERES) approach. We populate the paper with concrete examples of how QOL data need not be treated any different, in terms of statistical analysis, than tumor response or other clinical end points.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700 · cited 3×
“We suggest using the empirical rule effect size (ERES) method based on the ‘‘half standard deviation’’ moderate effect size for determining the a priori clinically significant change in QOL, which will be discussed in detail in a later section (Norman et al., 2003; Sloan et al., 2003b).”
BackgroundMethodSelf-citationAssessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309 · cited 2×
“Much has been written on the application of statistical methods for clinical trials (Altman et al., 2002; Juni et al., 2001; Pocock, 1996; Sloan et al., 1998c).”
Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods.
Aickin, M., & Gensler, H. (1996) · American Journal of Public Health · doi:10.2105/ajph.86.5.726 · Cited by 1,346
The truly remarkable universality of half a standard deviation: confirmation through another look
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2004) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.4.5.581 · Cited by 490
Self-citationSloan, J., Symonds, T., Vargas-Chanes, D., & Fridley, B. (2003) · Drug Information Journal · doi:10.1177/009286150303700105 · Cited by 242 · cited 7×
“Additionally, Sloan et al. (2003b) give more examples from the literature that are consistent with the half standard deviation definition of clinical significance.”
BackgroundMethodInfluentialSelf-citation
Cited by
Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.012 · Cited by 2,362
Self-citationCoons, S. J., Gwaltney, C. J., Hays, R. D., Lundy, J. J., Sloan, J. A., Revicki, D. A., Lenderking, W. R., Cella, D., & Basch, E. (2009) · Value in Health · doi:10.1111/j.1524-4733.2008.00470.x · Cited by 537
Self-citationRummans, T. A., Clark, M. M., Sloan, J. A., Frost, M. H., Bostwick, J. M., Atherton, P. J., Johnson, M. E., Gamble, G., Richardson, J., Brown, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.209 · Cited by 353
Self-citationWeder, W., Stahel, R. A., Bernhard, J., Bodis, S., Vogt, P., Ballabeni, P., Lardinois, D., Betticher, D., Schmid, R., Stupp, R., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm093 · Cited by 320
Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1
Loprinzi, C. L., Reeves, B. N., Dakhil, S. R., Sloan, J. A., Wolf, S. L., Burger, K. N., Kamal, A., Le-Lindqwister, N. A., Soori, G. S., Jaslowski, A. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0308 · Cited by 281
Self-citation
Metadata
- Authors
- Sloan, J. A., & Dueck, A.
- Venue
- Journal of Biopharmaceutical Statistics
- Publisher
- Informa UK Limited
- Published
- 2004-12-24
- Volume
- 14
- Issue
- 1
- Pages
- 73-96
- ISSN
- 1054-3406 (ISSN-L)
- 1520-5711
- OpenAlex
- W2039874252
- Cited by
- 144
- References
- 6
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Issues for Statisticians in Conducting Analyses and Translating Results for Quality of Life End Points in Clinical Trials. https://app.cochat.ai/papers/10.1081/bip-120028507
- The paper
- Sloan, J. A., & Dueck, A. (2004). Issues for Statisticians in Conducting Analyses and Translating Results for Quality of Life End Points in Clinical Trials. Journal of Biopharmaceutical Statistics. https://doi.org/10.1081/bip-120028507
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.